Literature DB >> 18992783

Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.

Manette T Niu1, Robert Ball, Emily Jane Woo, Dale R Burwen, Maureen Knippen, M Miles Braun.   

Abstract

During the period March 1, 1998 to January 14, 2007, approximately 6 million doses of Anthrax vaccine adsorbed (AVA) vaccine were administered. As of January 16, 2007, 4753 reports of adverse events following receipt of AVA vaccination had been submitted to the Vaccine Adverse Event Reporting System (VAERS). Taken together, reports to VAERS did not definitively link any serious unexpected risk to this vaccine, and review of death and serious reports did not show a distinctive pattern indicative of a causal relationship to AVA vaccination. Continued monitoring of VAERS and analysis of potential associations between AVA vaccination and rare, serious events is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18992783     DOI: 10.1016/j.vaccine.2008.10.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events.

Authors:  Leisha D Nolen; Rita M Traxler; Grishma A Kharod; Pallavi A Kache; Stefan Katharios-Lanwermeyer; Katherine A Hendricks; Sean V Shadomy; William A Bower; Dana Meaney-Delman; Henry T Walke
Journal:  Health Secur       Date:  2016-11-29

2.  Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Authors:  Bruce K Brown; Josephine Cox; Anita Gillis; Thomas C VanCott; Mary Marovich; Mark Milazzo; Tanya Santelli Antonille; Lindsay Wieczorek; Kelly T McKee; Karen Metcalfe; Raburn M Mallory; Deborah Birx; Victoria R Polonis; Merlin L Robb
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

3.  Immunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis Ames.

Authors:  James M Vergis; Christopher K Cote; Joel Bozue; Farhang Alem; Christy L Ventura; Susan L Welkos; Alison D O'Brien
Journal:  Clin Vaccine Immunol       Date:  2012-10-31

Review 4.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01

5.  Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.

Authors:  Xuejiao Pan; Huakun Lv; Fuxing Chen; Ying Wang; Hui Liang; Linzhi Shen; Yaping Chen; Yu Hu
Journal:  Hum Vaccin Immunother       Date:  2021-06-25       Impact factor: 4.526

6.  Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.

Authors:  David Martin; David Menschik; Marthe Bryant-Genevier; Robert Ball
Journal:  Drug Saf       Date:  2013-07       Impact factor: 5.228

7.  Making Common Sense of Vaccines: An Example of Discussing the Recombinant Attenuated Salmonella Vaccine with the Public.

Authors:  Dorothy J Dankel; Kenneth L Roland; Michael Fisher; Karen Brenneman; Ana Delgado; Javier Santander; Chang-Ho Baek; Josephine Clark-Curtiss; Roger Strand; Roy Curtiss
Journal:  Nanoethics       Date:  2014-07-10       Impact factor: 0.917

8.  A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China.

Authors:  Huakun Lv; Xuejiao Pan; Hui Liang; Yaping Chen; Ying Wang; Fuxing Chen; Linzhi Shen; Yu Hu
Journal:  Vaccines (Basel)       Date:  2022-02-17

Review 9.  Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Authors:  Jarad M Schiffer; Michael M McNeil; Conrad P Quinn
Journal:  Expert Rev Vaccines       Date:  2016-03-25       Impact factor: 5.683

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.